Ataca P, Soyturk M, Karaman M, Unlu M, Sagol O, Dervis Hakim G, Yilmaz O. Nilotinib-mediated mucosal healing in a rat model of colitis. World J Gastroenterol 2013; 19(37): 6237-6244 [PMID: 24115822 DOI: 10.3748/wjg.v19.i37.6237]
Corresponding Author of This Article
Dr. Pinar Ataca, Specialist, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Kültür Mh., Cumhuriyet Blv 144, Inciralti, Izmir 35340, Turkey. pinar@ataca.tk
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Pinar Ataca, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Inciralti, Izmir 35340, Turkey
Mujde Soyturk, Gozde Dervis Hakim, Department of Gastroenterology, Dokuz Eylul University School of Medicine, Inciralti, Izmir 35340, Turkey
Meral Karaman, Osman Yilmaz, Department of Laboratory Animal Science, Dokuz Eylul University School of Medicine, Inciralti, Izmir 35340, Turkey
Mehtat Unlu, Ozgul Sagol, Department of Pathology, Dokuz Eylul University School of Medicine, Inciralti, Izmir 35340, Turkey
Author contributions: Ataca P and Soyturk M contributed equally to this work; Ataca P and Soyturk M designed the research, drafted the manuscript, and obtained funding; Dervis Hakim G provided administrative and technical support; Unlu M and Sagol O contributed in analysis and interpretation of pathological data; and Karaman M and Yilmaz O contributed to the design of the rat experiments; all authors read and approved the final manuscript.
Supported by Dokuz Eylul University Research Committee, grant number 42/2010
Correspondence to: Dr. Pinar Ataca, Specialist, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Kültür Mh., Cumhuriyet Blv 144, Inciralti, Izmir 35340, Turkey. pinar@ataca.tk
Telephone: +90-232-4123707 Fax: +90-232-2599723
Received: June 14, 2013 Revised: August 7, 2013 Accepted: August 20, 2013 Published online: October 7, 2013 Processing time: 126 Days and 13.3 Hours
Core Tip
Core tip: Unresponsiveness to medical treatment in refractory inflammatory bowel disease (IBD) still poses a therapeutic challenge. To detect an alternative treatment option, we selected nilotinib based on the fact that tyrosine kinases inhibitors affect several key components in the pathogenesis of IBD, including tumor necrosis factor (TNF) alpha, platelet-derived growth factor receptor (PDGFR), and apoptosis. In a trinitrobenzene sulfonic acid-induced colitis rat model, we concluded that nilotinib has a significant effect on weight loss and on macroscopic and microscopic pathological scores, leading to significant mucosal healing. Although nilotinib caused a decrease in the PDGFR alpha and PDGFR beta levels, it did not have a significant effect on the apoptotic scores or TNF alpha levels.
